Welcome to our dedicated page for Allarity Therapeutics SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allarity Therapeutics, Inc. SEC filings document the company’s clinical-stage oncology business, capital structure, governance, and material-event disclosures. The filings identify Allarity’s Nasdaq-listed common stock and emerging growth company status, and include 8-K reports covering Regulation FD presentations, scientific and clinical updates for stenoparib and the DRP® companion diagnostic, intellectual-property developments, operating and financial results, and promissory-note financing.
Proxy materials describe annual meeting matters and stockholder voting procedures, while material definitive agreement filings and other current reports provide formal disclosure on financing arrangements, corporate progress, and regulatory or clinical communications tied to Allarity’s precision oncology programs.
Allarity Therapeutics, Inc. reported interim results showing constrained operations but sufficient near-term liquidity. The company recorded a net loss of $5.1 million for the six months ended June 30, 2025 and negative operating cash flow of $8.2 million over the same period. Management states that $17.8 million of cash, cash equivalents and restricted cash as of June 30, 2025 is estimated to be sufficient to fund operations for at least the next 12 months under the current plan. The company completed corporate actions including Reverse Stock Splits (retroactively applied) and repurchased 2,455,702 shares for $2,565,511, leaving $2,434,489 available under its repurchase program. A legal/contract liability to Novartis resulted in current liabilities recorded as $3.6 million accounts payable, $1.4 million convertible promissory notes and accrued interest, and $0.4 million accrued liabilities. The company settled a prior SEC investigation by paying a $2.5 million civil penalty which was paid in cash on April 2, 2025.
Allarity Therapeutics, Inc. filed a notice that its Quarterly Report on Form 10-Q for the period ended June 30, 2025 will be filed late. The company says its financial statements for the quarter are still being reviewed by its certifying auditors and that this review must be completed before the report can be finalized.
Management states that filing the Form 10-Q and related XBRL exhibit by the original deadline would require unreasonable effort or expense, but it reasonably believes the report will be completed and filed within the allowed five-day extension period.
On 15 Jul 2025 Allarity Therapeutics, Inc. (NASDAQ: ALLR) filed a Form 8-K under Item 8.01 to disclose the execution of a new commercial agreement with an undisclosed EU-based biotechnology company. The filing states only that the agreement was announced via a press release furnished as Exhibit 99.1, which is incorporated by reference.
No financial terms, partner identity, milestones, or projected revenue were provided in the 8-K, and the company did not report any changes to financial statements, guidance, or capital structure. Other 8-K items were not triggered. Investors must review Exhibit 99.1 for substantive economic details before assessing materiality.
Allarity Therapeutics has formally requested the withdrawal of its Form S-3 registration statement (File No. 333-281864) filed on August 30, 2024. The company has decided not to proceed with the planned public offering at this time.
Key points from the withdrawal request:
- The registration statement was never declared effective by the SEC
- No securities were issued or sold under this registration
- The company acknowledges no refund will be made for filing fees
- Allarity requests that paid fees be credited to offset future registration statement costs under Rule 457(p)
The withdrawal request, submitted by CEO Thomas H. Jensen on June 24, 2025, is made pursuant to Rule 477 under the Securities Act of 1933. This action indicates a significant shift in the company's capital raising strategy and could impact its near-term financing plans.